TrialJournal of clinical oncology : official journal of the American Society of Clinical Oncology2023

MANIFEST: Pelabresib in Combination With Ruxolitinib for Janus Kinase Inhibitor Treatment-Naïve Myelofibrosis.

John Mascarenhas et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.